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tethinking Loading
ose Clopidogrel in
ight of Increased Bleeding
omplications in Bypass Patients
he recent paper by Berger et al. (1) brings to light an important point
hat we think affects a majority of cardiologists and cardiac surgeons
like. The use of clopidogrel is now widespread, and the American
ollege of Cardiology/American Heart Association (ACC/AHA)
uidelines (2) highlight the indications for its use. However, more
ften we anecdotally observe indiscriminate use of loading dose
lopidogrel, especially by emergency room physicians and internists,
eading to delays in emergent or urgent coronary artery bypass grafting
CABG) and/or increased bleeding complications.
The guidelines (2) list a Class 1 indication for choosing between
lopidogrel or a glycoprotein IIb/IIIa inhibitor when an early
nvasive strategy is chosen in patients with unstable angina/non–
T-segment elevation myocardial infarction. The guidelines do
ot specify the timing of its use, and herein is where the problem
ies. It is reasonable to deduce from the current published data that
3) clopidogrel could be given during catheterization after coronary
natomy is determined, especially in patients going to catheteriza-
ion within 6 h and particularly in those patients that might need
ypass. These patients might be better served with more aggressive
se of other anticoagulants and glycoprotein IIb/IIIa inhibitors
hat are easily reversible, thereby circumventing having to wait 5
ays after loading dose clopidogrel.
A large study by Mehta et al. (4) showed that almost one-third
f patients needed CABG within 5 days of clopidogrel use. These
ad increased need for red cell transfusions.
Studies are lacking on how to discriminate who might need
ABG. Sadanandan et al. (5) did show that a validated risk
coring system might be applied to discriminate patients who
ight have a higher chance of needing CABG and thus holding
lopidogrel use until coronary anatomy is defined.
The authors feel that more widespread use of risk scoring
ystems might improve patient outcomes for CABG and better
iscriminate the need for loading dose clopidogrel, especially
ecause effective and quickly reversible anticoagulant agents have
een safely used and widely studied (e.g., glycoprotein IIb/IIIa
nhibitors).
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e thank Drs. Patel and Mascarenhas for their insightful com-
ents. Indeed, the management algorithm for patients with
nstable angina/non–ST-segment elevation myocardial infarction
oes provide Class I options for platelet-directed pharmacotherapy
n a background of aspirin, particularly among those in whom an
arly invasive strategy is selected according to validated risk scores
1). An ability to discriminate with a high degree of accuracy
mong patients likely to require surgical revascularization would
ndoubtedly facilitate a more targeted approach to pharmacother-
py, thereby avoiding delays, concomitant risks for recurring events
2), and perioperative hemorrhagic complications (3). Clearly the
mpact of treatment decisions is far-reaching, and might well
ecome an even greater challenge with the introduction of increas-
ngly robust platelet antagonists and their accompanying pro-
onged biological half-lives.
The preemptive identification of patients with surgical anatomy
t the time of presentation is not a simple task, with existing
odels providing modest predictive accuracy and calibration (4,5).
n addition, the ultimate decision to perform surgical over percu-
aneous revascularization is influenced by many factors—patient,
amily, physician, hospital, and healthcare system-specific consid-
rations each apply. The risk of hemorrhage is also influenced by
umerous variables not restricted to antithrombotic therapy (6).
The concomitant development and carefully designed investi-
ation of short-acting or readily reversible antithrombotic agents,
oint-of-care measurement devices that permit a clear assessment
f perioperative perturbation of hemostatic potential, and high-
hroughput platforms for advanced biomarkers to better predict
atient-specific risk of bleeding (7) will collectively enrich and
